World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 29 July 2024
Main ID:  NCT03645460
Date of registration: 17/07/2018
Prospective Registration: Yes
Primary sponsor: Shenzhen Geno-Immune Medical Institute
Public title: Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA)
Scientific title: Gene Therapy Via Intravenous Injection of Lentiviral Vector (Ivlv-ADA) for the Treatment of Adenosine Deaminase-severe Combined Immunodeficiency (ADA-SCID)
Date of first enrolment: June 30, 2024
Target sample size: 10
Recruitment status: Recruiting
URL:  https://clinicaltrials.gov/ct2/show/NCT03645460
Study type:  Interventional
Study design:  Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  N/A
Countries of recruitment
China
Contacts
Name:     Lung-Ji Chang, Ph.D
Address: 
Telephone:
Email:
Affiliation:  Shenzhen Geno-Immune Medical Institute
Name:     Lung-Ji Chang, Ph.D
Address: 
Telephone: 86-0755-86725195
Email: c@szgimi.org
Affiliation: 
Key inclusion & exclusion criteria
Inclusion Criteria:

- Diagnosis of classical ADA-SCID based on:

- A proven defective adenosine deaminase (ADA) gene as defined by direct
sequencing of patient DNA.

- T-cell immune deficiency defined as one or more of the following: CD3+
autologous T cells < 300/ul, or less than 50% of normal value for in vitro
mitogen stimulation, or absent proliferation in vitro to antigens.

- With severe infections, including but not limited to: pneumonitis; protracted
diarrhea requiring total parenteral nutrition; infection with herpes viruses or
adenovirus or fungus; disseminated BCG infection.

- No cytogenetic abnormalities (medullary karyotype) and no detection of main
rearrangements associated with acute leukemia of children.

- No prior allogeneic stem cell transplantation.

- Life expectancy = 2 months.

- Negative for HIV infection.

- Written, informed consent obtained prior to any study-specific procedures.

Exclusion Criteria:

- None



Age minimum: 1 Month
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)
Intervention(s)
Genetic: Direct intravenous injection of ivlv-ADA lentiviral vector
Primary Outcome(s)
Overall survival up to a year [Time Frame: 1 years]
Secondary Outcome(s)
2. Change of infection status [Time Frame: 12 month]
1. Success of immune reconstitution [Time Frame: 12 month]
Secondary ID(s)
GIMI-IRB-18003
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey